Table 1 Baseline characteristics in MHD patients with or without COVID-19
COVID19-infected patients N = 93 | Non-infected patients N = 53 | P | |
|---|---|---|---|
Age (yrs, median and IQR) | 60(47,68) | 57(45,67) | 0.5 |
Dialysis vintage (mean, median and IQR) | 65(43,92) | 68(43,95) | 0.7 |
Male sex (No, %) | 57(61.3) | 38(71.7) | 0.2 |
Vaccinations (No, %) | 16(17.2) | 7(13.2) | 0.7 |
Primary disease (No,%) | 0.97 | ||
Chronic glomerulonephritis | 35(38.5) | 20(37.8) | |
Diabetic nephropathy | 26(28.6) | 15(28.3) | |
Hypertensive nephropathy | 8(8.8) | 6(11.3) | |
Others | 22(24.2) | 12(22.6) | |
Coexisting disorders (No,%) | |||
Diabetes mellitus | 32(35.2) | 20(37.7) | 0.8 |
Cancer | 3(3.3) | 0 | 0.3 |
BMI (kg/m2, median and IQR) | 24.0(21.7,26.7) | 24.1(22.2,27.5) | 0.6 |
Monthly averaged pre-HD systolic BP (mmHg, mean ± SD) | 152.5 ± 16.0 | 153.4 ± 19.4 | 0.8 |
Monthly averaged pre-HD diastolic BP (mmHg, mean ± SD) | 79.3 ± 12.5 | 81.0 ± 13.0 | 0.4 |
KT/V (median and IQR) | 1.5(1.3,1.7) | 1.4(1.3,1.7) | 0.3 |
Weekly averaged EPO dose (IU, median and IQR) | 9000(6000,12000) | 6000(6000,9000) | 0.2 |
Hemoglobin (g/L, median and IQR) | 111(106,118) | 113(106,119) | 0.5 |
Albumin (g/L, mean ± SD) | 36.1 ± 3.4 | 36.7 ± 3.1 | 0.36 |
Potassium (mmol/L, mean ± SD) | 4.4 ± 0.6 | 4.4 ± 0.6 | 0.98 |
Sodium (mmol/L, mean ± SD) | 135.5 ± 3.6 | 137.6 ± 2.4 | < 0.0001 |
Ferritin (ng/L, median and IQR) | 537.0(340.2,814.6) | 386.2(185.0,650.8) | 0.006 |
Serum iron (umol/L, median and IQR) | 9.4(6.7,12.9) | 10.2(8.3,11.9) | 0.3 |
Leukocyte (10^9/l, median and IQR) | 5.5(4.3,6.8) | 6.1(4.5,7.5) | 0.43 |
Lymphocyte (10^9/l, median and IQR) | 0.9(0.7,1.2) | 0.9(0.8,1.2) | 0.8 |
C-reactive protein (mg/l, median and IQR) | 11.8(3.3,43.7) | 5.2(2.3,11.8) | 0.005 |
ALT (IU/L, median and IQR) | 10.0(8.0,18.0) | 10.0(7.0,14.0) | 0.6 |
AST (IU/L, median and IQR) | 17.0(12.0,23.0) | 13.0(11.0,17.0) | 0.003 |
ALP (IU/L, median and IQR) | 84.0(67.0,118.0) | 89.0(68.0,111.0) | 0.9 |